Detalhe da pesquisa
1.
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Blood
; 132(1): 67-77, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29784639
2.
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Blood
; 130(26): 2848-2859, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29042365
3.
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Blood
; 127(17): 2131-43, 2016 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26864341
4.
Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.
Blood
; 118(4): 1062-8, 2011 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-21653319
5.
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Cell Rep
; 23(11): 3127-3136, 2018 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898385
6.
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Mol Cancer Res
; 15(8): 967-972, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28634224
7.
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
J Clin Invest
; 127(6): 2392-2406, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28481221
8.
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
Cell Cycle
; 13(23): 3727-41, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25483082
9.
Drugging DNA repair to target T-ALL cells.
Leuk Lymphoma
; 59(7): 1746-1749, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29115896
10.
Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.
Cancer Res
; 71(16): 5381-6, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21693657